We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subc... Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. Show more
Ask ADVFN Intelligence (AI)
SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile On track to report Phase 2...
SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Pharmacokinetic data up to 9 months continue to support potential best-in-class profile, including a half-life of approximately 75 days, approximately three to five times that of currently...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -8.84 | -16.5171898356 | 53.52 | 53.52 | 44.11 | 451968 | 47.03738261 | CS |
| 4 | -7.14 | -13.7784639135 | 51.82 | 63.5 | 44.11 | 392079 | 53.68549629 | CS |
| 12 | -3.59 | -7.43733167599 | 48.27 | 63.5 | 44.11 | 417671 | 53.84524365 | CS |
| 26 | -7.26 | -13.9776665383 | 51.94 | 63.5 | 36.26 | 414262 | 48.50368118 | CS |
| 52 | 26.95 | 152.002256063 | 17.73 | 72.29 | 16.39 | 469239 | 48.97194927 | CS |
| 156 | 23.18 | 107.813953488 | 21.5 | 72.29 | 14.19 | 432864 | 43.0947616 | CS |
| 260 | 23.18 | 107.813953488 | 21.5 | 72.29 | 14.19 | 432864 | 43.0947616 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
